Illumina (ILMN) Stock Forecast & Price Target

$141.66 -3.49 (-2.40%)

(As of 12:03 PM ET)

Illumina - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 24 Analyst Ratings

Sell
1

Hold
8

Buy
15

Based on 24 Wall Street analysts who have issued ratings for Illumina in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 24 analysts, 1 has given a sell rating, 8 have given a hold rating, 13 have given a buy rating, and 2 have given a strong buy rating for ILMN.

Consensus Price Target

$164.00
15.77% Upside

According to the 24 analysts' twelve-month price targets for Illumina, the average price target is $164.00. The highest price target for ILMN is $254.00, while the lowest price target for ILMN is $100.00. The average price target represents a forecasted upside of 15.77% from the current price of $141.66.

Get the Latest News and Ratings for ILMN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Illumina and its competitors.

ILMN Analyst Ratings Over Time

Type	Current Forecast 12/4/23 to 12/3/24	1 Month Ago 11/4/23 to 11/3/24	3 Months Ago 9/5/23 to 9/4/24	1 Year Ago 12/4/22 to 12/4/23
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	13 Buy rating(s)	13 Buy rating(s)	12 Buy rating(s)	7 Buy rating(s)
Hold	8 Hold rating(s)	8 Hold rating(s)	9 Hold rating(s)	7 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	3 Sell rating(s)
Consensus Price Target	$164.00	$155.50	$151.05	$194.56
Forecasted Upside	15.77% Upside	3.83% Upside	17.46% Upside	70.16% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

Media Is Mocking Elon, But Wait Until They See This Demo (Ad)

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.

ILMN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ILMN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Illumina Stock vs. The Competition

Type	Illumina	Medical Companies	S&P 500
Consensus Rating Score	2.67	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	12.99% Upside	25,909.61% Upside	6.71% Upside
News Sentiment Rating	Positive News See Recent ILMN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/12/2024	Stephens 4 of 5 stars		Boost Target	Overweight ➝ Overweight	$170.00 ➝ $184.00	+21.45%
11/12/2024	Morgan Stanley 3 of 5 stars		Reiterated Rating	Equal Weight	$156.00	+2.97%
11/11/2024	Piper Sandler 2 of 5 stars		Lower Target	Overweight ➝ Overweight	$195.00 ➝ $185.00	+22.44%
11/6/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$124.00 ➝ $139.00	-10.30%
11/5/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Brennan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$166.00 ➝ $177.00	+15.02%
11/5/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$133.00 ➝ $145.00	-4.89%
Get the Latest News and Ratings for ILMN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.
11/5/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$252.00 ➝ $254.00	+68.04%
11/5/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$125.00 ➝ $140.00	-7.76%
11/5/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Donnelly Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$155.00 ➝ $190.00	+25.05%
11/5/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Sergott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$135.00 ➝ $145.00	-3.65%
11/5/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$130.00 ➝ $145.00	-5.53%
10/17/2024	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Gupta Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy	$180.00	+25.42%
10/17/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$160.00 ➝ $200.00	+38.91%
10/17/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$180.00	+25.10%
8/28/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Hellweg Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$150.00	+14.59%
8/16/2024	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Nakagiri Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/16/2024	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$120.00 ➝ $154.00	+19.57%
8/15/2024	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Sector Outperform ➝ Sector Outperform	$176.00 ➝ $164.00	+27.33%
6/11/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$195.00 ➝ $175.00	+59.35%
6/3/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$115.00	+10.28%
3/20/2024	OTR Global Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Positive ➝ Mixed
12/15/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underperform ➝ Market Perform
12/14/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$155.00	+22.37%
12/13/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$175.00	+48.76%
12/12/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underperform	$140.00 ➝ $100.00	-14.99%
10/12/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$200.00	+49.91%
8/10/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$225.00 ➝ $200.00	+8.41%
1/10/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$350.00 ➝ $296.00	+42.78%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 12:29 PM ET.

Should I Buy Illumina Stock? ILMN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, December 1, 2024. Please send any questions or comments about these Illumina pros and cons to contact@marketbeat.com.

Illumina
Bull Case

Here are some ways that investors could benefit from investing in Illumina, Inc.:

Illumina, Inc. recently reported earnings of $1.14 per share, exceeding analysts' expectations of $0.88, indicating strong financial performance and potential for growth.
The stock price is currently at $144.15, reflecting a 3.0% increase recently, which may suggest positive market sentiment and potential for further appreciation.
Institutional investors hold 89.42% of the stock, indicating strong confidence from large financial entities in Illumina, Inc.'s future prospects.
Illumina, Inc. operates in the rapidly growing life sciences sector, providing sequencing and array-based solutions for genetic analysis, which is increasingly in demand.
The company has a positive return on equity of 7.29%, suggesting effective management and the ability to generate profit from shareholders' equity.

Illumina
Bear Case

Investors should be bearish about investing in Illumina, Inc. for these reasons:

Illumina, Inc. has a negative net margin of 36.10%, indicating that the company is currently spending more than it earns, which could be a concern for profitability.
The revenue for the latest quarter was down 3.5% year-over-year, suggesting potential challenges in maintaining sales growth in a competitive market.
Despite a strong performance in earnings, the stock has a price-to-earnings ratio of -14.14, which may indicate that the stock is overvalued relative to its earnings.
Recent stock volatility, with a 52-week range from $99.23 to $156.66, may pose risks for investors looking for stability.
Only one analyst has rated the stock as a sell, while the majority have a hold or buy rating, which may indicate uncertainty about the stock's future performance.

ILMN Forecast - Frequently Asked Questions

: According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for Illumina is $164.00, with a high forecast of $254.00 and a low forecast of $100.00.
: 24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last twelve months. There is currently 1 sell rating, 8 hold ratings, 13 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ILMN shares.
: According to analysts, Illumina's stock has a predicted upside of 15.77% based on their 12-month stock forecasts.
: Over the previous 90 days, Illumina's stock had 2 upgrades by analysts.
: Illumina has been rated by research analysts at Barclays, Canaccord Genuity Group, Citigroup, Hsbc Global Res, HSBC, JPMorgan Chase & Co., Leerink Partners, Morgan Stanley, Piper Sandler, Robert W. Baird, Royal Bank of Canada, Stephens, TD Cowen, and UBS Group in the past 90 days.
: Analysts like Illumina less than other "medical" companies. The consensus rating score for Illumina is 2.67 while the average consensus rating score for "medical" companies is 2.81. Learn more on how ILMN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Media Is Mocking Elon, But Wait Until They See This Demo (Ad)

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.

This page (NASDAQ:ILMN) was last updated on 12/3/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Illumina (ILMN) Stock Forecast & Price Target